MYRIAD'S PHASE III ALZHEIMER'S DRUG TRIAL PROCEEDS

Myriad Genetics has begun enrollment for its Phase III trial of Flurizan in patients with mild stages of Alzheimer's disease is proceeding on schedule.

More than 120 sites across the U.S. have been enlisted and most are now screening and enrolling patients into the study. Myriad anticipates completing enrollment for the 12-month study during the first half of 2006 and reporting the results of the Phase III trial in the third calendar quarter of 2007.

Myriad used the results of its Phase II trial of Flurizan, which were presented at the Alzheimer's Association International Conference on Prevention of Dementia in June, to fine tune its Phase III trial. The Phase II study indicated that patients with mild Alzheimer's disease treated with 800 mg Flurizan twice daily, experienced the greatest benefit, with a 34 percent slowing in the rate of cognitive decline. This finding also guided Myriad to size the study to show statistical significance given a 30 percent improvement versus placebo with 90 percent confidence.